The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Allopurinol on the Progression of Chronic Kidney Disease
Open accessAbstract
BACKGROUND: Elevated serum urate levels are associated with progression of chronic kidney disease. Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known. METHODS: of body-surface area in the preceding year to receive allopurinol (100 to 300 mg daily) or placebo. The primary outcome was the change in eGFR from randomization to week 104, calculated with the Chronic Kidney Disease Epidemiology Collaboration creatinine equation. RESULTS: per year [95% CI, -1.18 to 0.97]; P = 0.85). Serious adverse events were reported in 84 of 182 patients (46%) in the allopurinol group and in 79 of 181 patients (44%) in the placebo group. CONCLUSIONS: In patients with chronic kidney disease and a high risk of progression, urate-lowering treatment with allopurinol did not slow the decline in eGFR as compared with placebo. (Funded by the National Health and Medical Research Council of Australia and the Health Research Council of New Zealand; CKD-FIX Australian New Zealand Clinical Trials Registry number, ACTRN12611000791932.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Elevated Uric Acid Increases the Risk for Kidney Disease
Obermayr, R. P., Temml, C., Gutjahr, G., Knechtelsdorfer, M., Oberbauer, R., & Klauser-Braun, R. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008010080 · Cited by 647
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Self-citationRisk Factors for End-Stage Renal Disease: 25-Year Follow-up
Hsu, C.-Y., Iribarren, C., McCulloch, C. E., Darbinian, J., & Go, A. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.605 · Cited by 589
Uric Acid and Incident Kidney Disease in the Community
Weiner, D. E., Tighiouart, H., Elsayed, E. F., Griffith, J. L., Salem, D. N., & Levey, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101075 · Cited by 462
Uric Acid and Long-term Outcomes in CKD
Madero, M., Sarnak, M. J., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Menon, V. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.021 · Cited by 436
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.028 · Cited by 383
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 377
Sircar, D., Chatterjee, S., Waikhom, R., Golay, V., Raychaudhury, A., Chatterjee, S., & Pandey, R. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.05.017 · Cited by 314
Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010007 · Cited by 310
Self-citationUric Acid as a Target of Therapy in CKD
Jalal, D. I., Chonchol, M., Chen, W., & Targher, G. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.021 · Cited by 268
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis
Bose, B., Badve, S. V., Hiremath, S. S., Boudville, N., Brown, F. G., Cass, A., de Zoysa, J. R., Fassett, R. G., Faull, R., Harris, D. C., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft378 · Cited by 222
Self-citationGrams, M. E., Sang, Y., Ballew, S. H., Matsushita, K., Astor, B. C., Carrero, J. J., Chang, A. R., Inker, L. A., Kenealy, T., Kovesdy, C. P., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010008 · Cited by 206
Jalal, D. I., Rivard, C. J., Johnson, R. J., Maahs, D. M., McFann, K., Rewers, M., & Snell-Bergeon, J. K. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp740 · Cited by 170
Jing, J., Kielstein, J. T., Schultheiß, U. T., Sitter, T., Titze, S. I., Schäeffner, E., McAdams‐DeMarco, M., Kronenberg, F., Eckardt, K., Köttgen, A., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu352 · Cited by 126
McMullan, C. J., Borgi, L., Fisher, N. D. L., Curhan, G. C., & Forman, J. P. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10771016 · Cited by 113
Hughes, K., Major, T. J., de Zoysa, J., Dalbeth, N., & Merriman, T. R. (2013) · Kidney International · doi:10.1038/ki.2013.353 · Cited by 86
Self-citationThe serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes
Ahola, A. J., Sandholm, N., Forsblom, C. M., Harjutsalo, V., Dahlström, E. H., & Groop, P. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.025 · Cited by 63
Challenges of conducting a trial of uric-acid-lowering therapy in CKD
Badve, S. V., Brown, F. G., Hawley, C. M., Johnson, D. W., Kanellis, J., Rangan, G. K., & Perkovic, V. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.186 · Cited by 61
Self-citationGlomerular filtration rate decline as a surrogate end point in kidney disease progression trials
Badve, S. V., Palmer, S. C., Hawley, C. M., Pascoe, E. M., Strippoli, G. F., & Johnson, D. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv269 · Cited by 56
Self-citationGarcía‐Hernandez, A., & Rizopoulos, D. (2018) · Journal of Statistical Software · doi:10.18637/jss.v084.i12 · Cited by 24
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Hyperuricemia and its related diseases: mechanisms and advances in therapy
Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01916-y · Cited by 631
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 377
Uric acid and cardiovascular disease: A clinical review
Saito, Y., Tanaka, A., Node, K., & Kobayashi, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.013 · Cited by 374
Metadata
- Authors
- Badve, S. V., Pascoe, E. M., Tiku, A., Boudville, N., Brown, F. G., Cass, A., Clarke, P., Dalbeth, N., Day, R. O., de Zoysa, J. R., Douglas, B., Faull, R., Harris, D. C., Hawley, C. M., Jones, G. R. D., Kanellis, J., Palmer, S. C., Perkovic, V., Rangan, G. K., Reidlinger, D., Robison, L., Walker, R. J., Walters, G., & Johnson, D. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-06-25
- Volume
- 382
- Issue
- 26
- Pages
- 2504-2513
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3038080478
- Cited by
- 473
- References
- 25
- FWCI
- 37.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.